Tag: 娱乐地图QIG

TGFb inhibitors Pipeline Insight Report 2021: In 2020, Bristol Myers Squibb Enters Agreement to…

first_img Pinterest TAGS  WhatsApp TGFb inhibitors Pipeline Insight Report 2021: In 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio – ResearchAndMarkets.com Pinterest Local NewsBusiness WhatsApp Twitter Facebook How many companies are developing TGFb inhibitors drugs?How many TGFb inhibitors drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for TGFb inhibitors?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TGFb inhibitors therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for TGFb inhibitors and their status?What are the key designations that have been granted to the emerging drugs? Key PlayersAcceleron PharmaIsarna TherapeuticsForbius Key PlayersLuspaterceptISTH0036ISTH1106ISTH0047ISTH1047AVID 200 For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2fdjhj View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005190/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/19/2021 04:46 AM/DISC: 02/19/2021 04:46 AM http://www.businesswire.com/news/home/20210219005190/en Twitter By Digital AIM Web Support – February 19, 2021 Previous articleEverbridge annuncia di essersi aggiudicata cinque contratti relativi alle soluzioni Public Warning con società di trasmissioni wireless, governi e Stati finalizzati alla protezione delle persone e delle aziende in Europa e in AsiaNext articleWilliams career-high 32 sparks WSU to romp over Cal 82-51 Digital AIM Web Support DUBLIN–(BUSINESS WIRE)–Feb 19, 2021– The “TGFb inhibitors – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. The companies and academics are working to assess challenges and seek opportunities that could influence TGFb inhibitors R&D. The therapies under development are focused on novel approaches for TGFb inhibitors. In July 2020, Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio. TGFb inhibitors Emerging Drugs Chapters This segment of the TGFb inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. TGFb inhibitors Emerging DrugsLuspatercept – Acceleron Pharma Luspatercept-aamt is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients who have serious blood disorders associated with ineffective erythropoiesis. Discovered by scientists at Acceleron, luspatercept-aamt is a recombinant fusion protein that binds several TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling. TGFb inhibitors: Therapeutic Assessment This segment of the report provides insights about the different TGFb inhibitors drugs segregated based on following parameters that define the scope of the report, such as: Major Players working on TGFb inhibitors There are approx. 10+ key companies which are developing the TGFb inhibitors. The companies which have their TGFb inhibitors drug candidates in the most advanced stage, i.e. phase III include, Luspatercept. The report covers around 10+ products under different phases of clinical development likeLate-stage products (Phase III andMid-stage products (Phase II andEarly-stage products (Phase I/II and Phase I) along with the details ofPre-clinical and Discovery stage candidatesDiscontinued & Inactive candidatesRoute of Administration TGFb inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such asInfusionIntradermalIntramuscularIntranasalIntravaginalOralParenteralSubcutaneousTopicalMolecule Type Products have been categorized under various Molecule types such asVaccinesMonoclonal AntibodyPeptidesPolymerSmall moleculeProduct Type The drugs have been categorized under various product types like Mono, Combination and Mono/Combination. TGFb inhibitors: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses TGFb inhibitors therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TGFb inhibitors drugs. TGFb inhibitors Report InsightsTGFb inhibitors Pipeline AnalysisTherapeutic AssessmentUnmet NeedsImpact of Drugs TGFb inhibitors Report AssessmentPipeline Product ProfilesTherapeutic AssessmentPipeline AssessmentInactive drugs assessmentUnmet Needs Key Questions Answered Current Scenario and Emerging Therapies: Facebooklast_img read more